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We report the clinical presentation and laboratory findings of a 69-year-old man with fragile X-associated tremor ataxia syndrome
(FXTAS), a progressive neurodegenerative disorder, who was noted to havemonoclonal gammopathy of undetermined significance
(MGUS), a plasma cell proliferative disorder and a precursor disease of multiple myeloma. Both MGUS and FXTAS are associated
with microRNA (miRNA) dysregulation. We speculate that individuals with FXTAS may be predisposed to MGUS and further
studies are warranted regarding this association.
1. Introduction
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an
adult progressive neurodegenerative disorder that aﬀects pre-
dominantly male carriers of the fragile X mental retardation
1 (FMR1) gene premutation (CGG expansion of 55–200 re-
peats). The clinical features of FXTAS are progressive inten-
tion tremor, cerebellar ataxia, autonomic dysfunction, pe-
ripheral neuropathy, cognitive decline, middle cerebellar pe-
duncle signs (MCPs), and white matter disease combined
with brain atrophy on MRI [1–4].
The penetrance of FXTAS in male carriers older than age
50 is approximately 30 to 45.5% and 8 to 16.5% in females [2,
5, 6]. Overproduction of the FMR1 mRNA, up to 8 fold times
normal, is the basic mechanism of FXTAS [7]. The elevated
FMR1 mRNA causes a gain-of-function toxicity to cells lead-
ing to the formation of intranuclear inclusions in neurons
and astrocytes throughout the central nervous system (CNS)
and subsequent sequestration of critical proteins necessary
for normal cell function [8, 9]. Mitochondrial dysfunction
also occurs in older premutation carriers both with and
without FXTAS [10, 11]. This cellular dysfunction leads to
neuronal cell death and white matter disease in the CNS
[3, 12, 13] associated with the clinical features of FXTAS.
Monoclonal gammopathy of undetermined significance
(MGUS) is a plasma cell proliferative disorder characterized
by a plasma cell level of less than 10% in the bone marrow,
a monoclonal paraprotein band less than 30 g/L, and no end
organ damage (CRAB—hypercalcemia, renal insuﬃciency,
anemia, and bone lesions) [14]. It is an age-related medical
condition found predominantly in older persons [15]. The
diagnosis of MGUS is usually an unexpected event during
an evaluation, and because it is typically asymptomatic,
it is underdiagnosed [16]. However, some abnormalities
such as bone loss or osteoporosis, peripheral neuropathy,
and thromboembolic events can be associated to this
disorder [17]. Individuals with MGUS have a higher risk of
developing multiple myeloma (MM) or related malignancy
[18–20]. Race, ethinicity, advance age, male sex [15], family
history [21], and exposure to certain pesticides [22] increase
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the risk of MGUS indicating that MGUS is a multifactorial
condition.
The pathogenesis of MGUS is hypothesized to begin with
an abnormal response to antigenic stimulation mediated by
toll-like receptors (TLRs) and interleukin IL-6 receptors and
IL-1β [23, 24]. This results in cytogenetic abnormalities—
either hyperdiploidy or immunoglobulin heavy chain (IgH)
translocations [25]. When it is followed by the second
hit including RAS or p53 mutation, p18 deletion, myc
dysregulation, MGUS progression to MM then occurs [26].
Dysregulation of microRNAs (miRNAs), the small non-
coding RNAs involved in posttranscriptional gene regula-
tion, plays a role inMGUS progression toMM [27]. MiRNAs
have been demonstrated to play a role in regulation of
apoptosis, proliferation, diﬀerentiation, cell survival, and
oncogenesis [28]. Abnormal miRNA regulation may lead to
oncogenesis, particularly MM [29–31]. The miRNA profiles
discrepantly expressed in MGUS also show similar aberrant
expression in MM suggesting the role of miRNAs in early
myelomagenesis [27].
MiRNAs are encoded throughout the genome and are
transcribed into pri-miRNA. The pri-miRNA is cleaved in
the nucleus by the Drosha RNase III endonuclease. Pre-
miRNAs are transported to the cytoplasm. In cytoplasm,
Dicer, a ribonuclease III, cleaves the pre-miRNA into the
mature miRNA which forms a complex with RNA-induced
silencing complex (RISC). This complex directs the miRNA
to the target mRNA leading either to degradation of target
mRNA or translational repression [32]. In FXTAS patients,
there is Drosha/DGCR8 sequestration by the elevated FMR1
mRNAs that leads to global miRNA dysregulation [33].
We speculate that this global miRNA dysregulation may
predispose individuals to MGUS. Here we report the clinical
presentation and laboratory findings of a man with FXTAS
and MGUS.
2. Clinical Report
A 69-year-old Caucasian man with FXTAS had a premu-
tation of 98 to 103 CGG repeats and an FMR1 mRNA
level of 2.33 ± 0.02 times normal. His intention tremor
began at age 55 and has been progressive. Currently, it
interferes with his activities of daily living (ADL) including
eating and handwriting. His gait imbalance began at age
58 and he started using a walker at age 66. His short-
term memory problems began at age 63. His stamina has
decreased significantly over the last few years and he has
some decreased sensation in his lower legs in addition to
pain with walking. He has autonomic dysfunction including
bladder incontinence and erectile dysfunction beginning at
age 66. His past medical history includes hypertension, type
2 diabetes, hyperlipidemia, hypothyroidism, sleep apnea, and
migraine headaches (Table 1).
His family history includes a carrier daughter with fragile
X-associated primary ovarian insuﬃciency (FXPOI). His
brother has had severe FXTAS with two surgeries for deep
brain stimulation. His mother, a carrier, has also had tremor,
cognitive decline, and non-Hodgkin’s lymphoma and it is
likely that she also has FXTAS.
Table 1: FXTAS clinical, neuroimaging, and molecular results of
the patient.
Intention tremor began at age 55
Right upper extremity
Postural tremor (+)
Kinetic tremor (+)
Left upper extremity
Postural tremor (+)
Kinetic tremor (+)
Handwriting problems began at age 58
Balance problem began at age 58
Type of gait Ataxic and broad based
Dependent on walker Began at age 66
Memory problems Began at age 63
Fragile X DNA test (CGG repeat
number)
98–103 (premutation range)
FMR1 mRNA level 2.33 ± 0.02 times normal
FXTAS diagnosis Definite
FXTAS stage 4
On physical examination, his blood pressure was
167/62mmHg, the heart rate was 71 bpm, the head cir-
cumference was 59.5 cm, his height was 172.7 cm, and
his weight was 87.5 kg. The ears were slightly prominent.
His neurological examination was abnormal with a severe
intention tremor with finger to nose touching but absent
at rest. There were no deep tendon reflexes but positive
primitive reflexes including the snout reflex. His vibration
sense was decreased in both feet. His gait was ataxic and
broad based. He cannot tandem walk and he had a positive
pull test. OnMRI, he had significant brain atrophy and white
matter disease including a positive MCP sign.
As a part of a workup for his mild normocytic ane-
mia, serum protein electrophoresis with immunofixation
revealed 1 g/dL IgG kappa monoclonal paraproteinemia. His
serum creatinine was mildly elevated at 1.3mg/dL with
estimated GFR of 55mL/min. Calcium and highly sensitive
C-reactive protein were within the normal reference range.
The quantitative immunoglobulins revealed normal IgG and
IgA levels with decreased IgM (17mg/dL; lower reference
range 37mg/dL). The free kappa light chain is elevated at
7.81mg/dL (upper reference range 1.92mg/dL) with normal
lambda light chain (1.88mg/dL). The kappa to lambda light
chain ratio was elevated at 4.15 (upper reference range 1.65).
The beta-2 microglobulin is elevated at 3.38mcg/mL (upper
reference range 1.8mcg/mL). The skeletal survey did not
reveal any lytic or sclerotic lesions. The bone marrow biopsy
revealed a normocellular marrow (30% cellularity) with less
than 5% kappa light chain restricted plasma cells (Table 2).
3. Discussion
This is the first clinical report of MGUS in an individual with
FXTAS. Although MGUS is an asymptomatic condition, it
is associated with peripheral neuropathy, osteoporosis, and
thromboembolic events. Symptoms shared by FXTAS and
MGUS include peripheral neuropathy. His risk factors for
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Table 2: MGUS laboratory workup of the patient.
Levels Reference range
Red cell count 3.82 4.5–5.9M/MM3 Low
Hemoglobin 11.9 13.5–17.5 GM/DL Low
Hematocrit 34.7 41–53% Low
Glucose 358 70–110mg/dL High
Hemagobin A1C 8.5 3.9–5.9% High
Calcium 9.5 8.6–10.5mg/dL Normal
Serum protein electrophoresis with
immunofixation
1 g/dL IgG kappa monoclonal paraproteinemia
Serum creatinine 1.3mg/dL 0.6–1.2mg/dL Mildly elevated
GFR 55 >60 Low
IgM 17mg/dL 37mg/dL–50mg/dL Decreased
Free kappa light chain 7.81mg/dL 0.33–1.92mg/dL Elevated
Lambda light chain 1.88mg/dL 0.57–2.63mg/dL Normal
Kappa to lambda light chain ratio 4.15 0.26–1.65 Elevated
Beta-2 microglobulin 3.38mcg/mL 1.8mcg/mL Elevated
Bone survey No lytic or sclerotic lesions
developing an MGUS included advancing age, male sex,
and having a mother with non-Hodgkin’s lymphoma, a
hematologic cancer. We also suggest that those with FXTAS
have a greater risk for MGUS through the common finding
of miRNA dysregulation in both disorders.
The DROSHA/DGCR8 sequestration mechanism in
FXTAS leads to miRNA alteration, specifically downregula-
tion of several miRNAs [33]. Thus, it may play a role in
oncogenesis and tumor biology through posttrancriptional
gene regulation impacting the mechanism of proliferation,
diﬀerentiation, apoptosis, metastasis, and cell survival [28].
In MGUS, miRNAs play an important role in early changes
associated with the development of the abnormal clonal
plasma cell and have a potential role in altering the p53
pathway [29]. Downregulation or absence of miRNAs has
been reported inmany cancers [34], including other hemath-
ologic malignancies such as acute myeloid leukemia [35],
chronic lymphocytic leukemia [36], and diﬀuse large B-cell
lymphoma [37].
It is unknownwhether there is an increased risk of having
cancer in those with a gene premutation, although there is
one case report of a man with lung tumor and full mutation
where the tumor’s origin was in a cell with premutation
instead of full mutation, indicating that the neoplasia de-
velopment may have been facilitated by the premutation
[38]. There is a relationship between elevated mRNA and
cyclic adenosine monophosphate (cAMP) response-element
binding protein (CREB). The elevated mRNA is due to
increased trancription [7], while CREB is involved in FMR1
transcriptional activity [39] and may play a role in oncoge-
nesis by various mechanisms including gene amplification,
chromosome translocation, interaction with viral oncopro-
tein, and inactivation of tumor supressor genes [40].
The current report of MGUS and FXTAS combined
with the commonality of miRNA mechanisms in these
two conditions suggests that this association may be more
common than previously realized and this deserves further
study. One possibility is screening for the premutation when
MGUS is identified. This would be very important if FXTAS
symptoms are present or if there is a family history of frag-
ile X-associated disorders including FXPOI or fragile X syn-
drome or autism.
Conflict of Interests
Dr. Hagerman has received funding from Novartis, Roche,
Seaside Theurapetics, Forest and Curemark for therapeutic
trials in fragile X syndrome and autism.
Acknowledgments
This work was supported by the National Institute of Health
grants HD036071 and HD02274; Neurotherapeutic Research
Institute (NTRI) grants DE019583 and DA024854; National
Institute on Aging grants AG032119 and AG032115;
National Center for Resources UL1 RR024146; and Health
and Human Services Administration of Developmental
Disabilities grant 90DD05969. The authors thank the family
who participated to this study. The first author is addressee
of Beasiswa Unggulan (The Excellent Scholarship) Program
of The Bureau of Planning and International Cooperation,
Ministry of National Education, Government of Indonesia.
References
[1] S. Jacquemont, R. J. Hagerman, M. Leehey et al., “Fragile
X premutation tremor/ataxia syndrome: molecular, clinical,
and neuroimaging correlates,” American Journal of Human
Genetics, vol. 72, no. 4, pp. 869–878, 2003.
[2] S. M. Coﬀey, K. Cook, N. Tartaglia et al., “Expanded clinical
phenotype of women with the FMR1 premutation,” American
4 Case Reports in Genetics
Journal of Medical Genetics, Part A, vol. 146, no. 8, pp. 1009–
1016, 2008.
[3] J. S. Adams, P. E. Adams, D. Nguyen et al., “Volumetric brain
changes in females with fragile X-associated tremor/ataxia
syndrome (FXTAS),” Neurology, vol. 69, no. 9, pp. 851–859,
2007.
[4] E. Berry-Kravis, C. G. Goetz, M. A. Leehey et al., “Neuropathic
features in fragile X premutation carriers,” American Journal of
Medical Genetics, Part A, vol. 143, no. 1, pp. 19–26, 2007.
[5] L. Rodriguez-Revenga, I. Madrigal, J. Pagonabarraga et al.,
“Penetrance of FMR1 premutation associated pathologies in
fragile X syndrome families,” European Journal of Human
Genetics, vol. 17, no. 10, pp. 1359–1362, 2009.
[6] S. Jacquemont, R. J. Hagerman, M. A. Leehey et al., “Pene-
trance of the fragile X-associated tremor/ataxia syndrome in
a premutation carrier population,” Journal of the American
Medical Association, vol. 291, no. 4, pp. 460–469, 2004.
[7] F. Tassone, A. Beilina, C. Carosi et al., “Elevated FMR1 mRNA
in premutation carriers is due to increased transcription,”
RNA, vol. 13, no. 4, pp. 555–562, 2007.
[8] D. Garcia-Arocena and P. J. Hagerman, “Advances in under-
standing the molecular basis of FXTAS,” Human Molecular
Genetics, vol. 19, no. 1, Article ID ddq166, pp. R83–R89, 2010.
[9] C. Sellier, F. Rau, Y. Liu et al., “Sam68 sequestration and
partial loss of function are associated with splicing alterations
in FXTAS patients,” EMBO Journal, vol. 29, no. 7, pp. 1248–
1261, 2010.
[10] C. Ross-Inta, A. Omanska-Klusek, S. Wong et al., “Evi-
dence of mitochondrial dysfunction in fragile X-associated
tremor/ataxia syndrome,” Biochemical Journal, vol. 429, no. 3,
pp. 545–552, 2010.
[11] E. Napoli, C. Ross-Inta, S. Wong et al., “Altered zinc transport
disrupts mitochondrial protein processing/import in frag-
ile X-associated tremor/ataxia syndrome,” Human Molecular
Genetics, vol. 20, no. 15, pp. 3079–3092, 2011.
[12] C. M. Greco, R. F. Berman, R. M. Martin et al., “Neuropathol-
ogy of fragile X-associated tremor/ataxia syndrome (FXTAS),”
Brain, vol. 129, part 1, pp. 243–255, 2006.
[13] R. Hashimoto, A. Javan, F. Tassone, R. J. Hagerman, and S. M.
Rivera, “A voxel-based morphometry study of grey matter loss
in fragile X-associated tremor/ataxia syndrome,” Brain, vol.
134, no. 3, pp. 863–878, 2011.
[14] R. A. Kyle, J. A. Child, K. Anderson et al., “Criteria for
the classification of monoclonal gammopathies, multiple
myeloma and related disorders: a report of the International
Myeloma Working Group,” British Journal of Haematology,
vol. 121, no. 5, pp. 749–757, 2003.
[15] R. A. Kyle, T. M. Therneau, S. V. Rajkumar et al., “Prevalence
of monoclonal gammopathy of undetermined significance,”
The New England Journal of Medicine, vol. 354, no. 13, pp.
1362–1369, 2006.
[16] R. A. Kyle and S. Kumar, “The significance of monoclonal
gammopathy of undetermined significance,” Haematologica,
vol. 94, no. 12, pp. 1641–1644, 2009.
[17] J. P. Bida, R. A. Kyle, T. M. Therneau et al., “Disease
associations with monoclonal gammopathy of undetermined
significance: a population-based study of 17,398 patients,”
Mayo Clinic Proceedings, vol. 84, no. 8, pp. 685–693, 2009.
[18] R. A. Kyle, “Monoclonal gammopathy of undetermined
significance. Natural history in 241 cases,” American Journal
of Medicine, vol. 64, no. 5, pp. 814–826, 1978.
[19] R. A. Kyle, T. M. Therneau, S. V. Rajkumar, D. R. Larson, M. F.
Plevak, and L. J. Melton, “Long-term follow-up of 241 patients
with monoclonal gammopathy of undetermined significance:
the original Mayo Clinic series 25 years later,” Mayo Clinic
Proceedings, vol. 79, no. 7, pp. 859–866, 2004.
[20] R. A. Kyle, ““Benign” monoclonal gammopathy—after 20 to
35 years of follow-up,” Mayo Clinic Proceedings, vol. 68, no. 1,
pp. 26–36, 1993.
[21] C. M. Vachon, R. A. Kyle, T. M. Therneau et al., “Increased
risk of monoclonal gammopathy in first-degree relatives of
patients with multiple myeloma or monoclonal gammopathy
of undetermined significance,” Blood, vol. 114, no. 4, pp. 785–
790, 2009.
[22] O. Landgren, R. A. Kyle, J. A. Hoppin et al., “Pesticide exposure
and risk of monoclonal gammopathy of undetermined signif-
icance in the Agricultural Health Study,” Blood, vol. 113, no.
25, pp. 6386–6391, 2009.
[23] G. Jego, R. Bataille, A. Geﬀroy-Luseau, G. Descamps, and C.
Pellat-Deceunynck, “Pathogen-associated molecular patterns
are growth and survival factors for human myeloma cells
through toll-like receptors,” Leukemia, vol. 20, no. 6, pp. 1130–
1137, 2006.
[24] C. A. Dinarello, “Targeting the pathogenic role of interleukin
1β in the progression of smoldering/indolent myeloma to
active disease,” Mayo Clinic Proceedings, vol. 84, no. 2, pp. 105–
107, 2009.
[25] P. L. Bergsagel andW.M. Kuehl, “Chromosome translocations
in multiple myeloma,” Oncogene, vol. 20, no. 40, pp. 5611–
5622, 2001.
[26] P. L. Bergsagel and W. M. Kuehl, “Molecular pathogenesis and
a consequent classification of multiple myeloma,” Journal of
Clinical Oncology, vol. 23, no. 26, pp. 6333–6338, 2005.
[27] K. R. Calvo, O. Landgren, A. M. Roccaro, and I. M. Gho-
brial, “Role of microRNAs from monoclonal gammopathy of
undetermined significance to multiple myeloma,” Seminars in
Hematology, vol. 48, no. 1, pp. 39–45, 2011.
[28] V. Ambros, “The functions of animal microRNAs,” Nature,
vol. 431, no. 7006, pp. 350–355, 2004.
[29] F. Pichiorri, S. S. Suh, M. Ladetto et al., “MicroRNAs regulate
critical genes associated withmultiple myeloma pathogenesis,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 105, no. 35, pp. 12885–12890, 2008.
[30] Y. Zhoua, L. Chena, B. Barlogiea et al., “High-risk myeloma
is associated with global elevation of miRNAs and overexpres-
sion of EIF2C2/AGO2,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 107, no. 17, pp.
7904–7909, 2010.
[31] N. C. Gutie´rrez, M. E. Sarasquete, I. Misiewicz-Krzeminska
et al., “Deregulation of microRNA expression in the diﬀerent
genetic subtypes of multiple myeloma and correlation with
gene expression profiling,” Leukemia, vol. 24, no. 3, pp. 629–
637, 2010.
[32] D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism,
and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.
[33] C. Sellier, P. Hagerman, and R. Willemsen, “DROSHA/
DGCR8 sequestration by expanded CGG repeats leads to
global micro-RNA processing alteration in FXTAS patients
[abstract],” in Proceedings of the 12th International Fragile X
Conference, Detroit, Mich, USA, 2010.
[34] J. Lu, G. Getz, E. A. Miska et al., “MicroRNA expression pro-
files classify human cancers,” Nature, vol. 435, no. 7043, pp.
834–838, 2005.
[35] M. Jongen-Lavrencic, S. M. Sun, M. K. Dijkstra, P. J. M. Valk,
and B. Lo¨wenberg, “MicroRNA expression profiling in rela-
tion to the genetic heterogeneity of acute myeloid leukemia,”
Blood, vol. 111, no. 10, pp. 5078–5085, 2008.
Case Reports in Genetics 5
[36] R. Visone, L. Z. Rassenti, A. Veronese et al., “Karyotype-spe-
cific microRNA signature in chronic lymphocytic leukemia,”
Blood, vol. 114, no. 18, pp. 3872–3879, 2009.
[37] J. Zhang, D. D. Jima, C. Jacobs et al., “Patterns of microRNA
expression characterize stages of human B-cell diﬀerentia-
tion,” Blood, vol. 113, no. 19, pp. 4586–4594, 2009.
[38] E. de Graaﬀ, R. Willemsen, N. Zhong et al., “Instability of
the CGG repeat and expression of the FMR1 protein in a
male fragile X patient with a lung tumor,” American Journal
of Human Genetics, vol. 57, no. 3, pp. 609–618, 1995.
[39] K. T. Smith, R. D. Nicholls, and D. Reines, “The gene encoding
the fragile X RNA-binding protein is controlled by nuclear
respiratory factor 2 and the CREB family of transcription
factors,” Nucleic Acids Research, vol. 34, no. 4, pp. 1205–1215,
2006.
[40] Y. T. Siu and D. Y. Jin, “CREB—a real culprit in oncogenesis,”
FEBS Journal, vol. 274, no. 13, pp. 3224–3232, 2007.
